Email this article 
Assessment of ERBB2 and HER2 expression in metastatic breast cancer using the nCounter® system and a 100-gene scale
- Authors: Paltuev R.M.1,2, Volynshchikova .A.2, Abdullaeva .R.2, Aleksakhina S.N.2, Artemyeva .S.2, Baychorov .A.3, Bakharev S.Y.4, Belaya Y.A.5, Bozhok .A.6, Vasin .A.7, Vladimirov V..8, Vorontsov A.Y.9, Gaysina E..10, Gofman A.A.4, Dmitriev .N.11, Imyanitov .N.2, Klimenko .V.2, Komyakhov A.V.2, Konstantinova M.M.1, Kopp M.V.12, Kudaybergenova A.G.2, Lalak .A.3, Matevosyan D.L.8, Mudzhiri N.M.13, Poltareva O.V.7, Sevryukova .I.3, Semiglazov V.F.2, Semiglazova T.Y.2, Urezkova M.M.2, Chichkanova A.S.9, Churilova L.A.4, Shomova M.V.14
-
Affiliations:
- Public organization «Russian Society of Oncomammologists»
- N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
- Stavropol Regional Clinical Oncology Dispensary
- Altai Regional Oncology Dispensary
- District Clinical Hospital
- Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia
- Ivanovo Regional Oncology Dispensary
- Pyatigorsk Regional Oncology Dispensary
- Nizhny Novgorod Regional Clinical Oncology Dispensary
- Multidisciplinary Clinical Medical Center «Medical City»
- Belgorod Regional Oncology Dispensary
- Private Medical University «Reaviz»
- Research Center of Neurology
- Regional Clinical Oncology Dispensary
- Issue: Vol 19, No 3 (2023)
- Pages: 30-36
- Section: MAMMOLOGY. ORIGINAL REPORTS
- Published: 27.10.2023
- URL: https://ojrs.abvpress.ru/ojrs/article/view/1116
- DOI: https://doi.org/10.17650/1994-4098-2023-19-3-30-36
- ID: 1116
Cite item
Full Text
Abstract
Background. Individual molecular characteristics of a tumor can serve as a basis for a tailored approach to therapy, prediction of the disease course and outcome, and timely treatment correction in cancer patients. Tumor genomic profiling allows for a more precise tumor assessment in an individual manner. Accurate identification of the HER2 status of a breast tumor is crucial for clinical decisions and appropriate treatment strategy.
Aim. To increase the efficacy of systemic therapy for breast cancer, reduce inappropriate prescribing, and ensure a tailored approach to systemic breast cancer therapy using the information on individual molecular characteristics of the tumor.
Materials and methods. We explored the expression of 100 genes involved in breast cancer development in 106 tumor samples from patients with metastatic breast cancer. We used the nCounter technology based on direct digital target detection using color-coded molecular barcodes. We analyzed the expression of 28 genes with a high predictive value for breast cancer.
Results. The nCounter technology allowed us to perform semiquantitative assessment of the expression of 28 genes in tumor tissue samples. We compared the expression of ERBB2 and HER2. The HER2 expression between 252.32 and 6000 barcodes was equivalent to HER2 (0) status; between 6000 and 9196.25 barcodes, to HER2 (1+); between 9196.25 and 15022.46, to HER2 (2+/ISH±); and 15022.46 barcodes, to HER2 (3+). In case of HER2 (3+) and ERBB2 below 6000 barcodes, the result was considered false positive. In case of HER2 (0) or (1+) and ERBB2 above 15 000 barcodes, the result was considered false negative. In 18 tumors, the discrepancies in the results meant two principally different breast cancer subtypes requiring different treatments; in 2 cases, the discrepancies were in the level of HER2 expression.
Conclusion. HER2 testing should be performed on an excision sample (ideally on the same block that was used for genomic testing). Despite the correlation between the HER2-enriched molecular class and the response to anti-HER2 therapy, the final result on HER2 status in discordant cases should be based on currently approved assays after results validation.
About the authors
R. M. Paltuev
Public organization «Russian Society of Oncomammologists»; N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
Author for correspondence.
Email: paltuev@mail.ru
ORCID iD: 0000-0002-0871-9453
Ruslan Malikovich Paltuev
56 Prospekt Veteranov, Saint Petersburg 198255;
68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758
O. A. Volynshchikova
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
ORCID iD: 0009-0001-9454-1320
68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758
Russian FederationSh. R. Abdullaeva
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
ORCID iD: 0000-0002-6601-2528
68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758
Russian FederationS. N. Aleksakhina
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
ORCID iD: 0000-0002-2149-7728
68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758
Russian FederationA. S. Artemyeva
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
ORCID iD: 0000-0002-2948-397X
68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758
Russian FederationE. A. Baychorov
Stavropol Regional Clinical Oncology Dispensary
ORCID iD: 0000-0002-6292-1775
82а Oktyabrskaya St., Stavropol 355047
Russian FederationS. Yu. Bakharev
Altai Regional Oncology Dispensary
110k Zmeinogorskiy Trakt, Barnaul 656045
Russian FederationYu. A. Belaya
District Clinical Hospital
ORCID iD: 0009-0006-0709-3686
40 Kalina St., Khanty-Mansiysk 628011
Russian FederationA. A. Bozhok
Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia
2 Litovskaya St., Saint Petersburg 194100
Russian FederationV. A. Vasin
Ivanovo Regional Oncology Dispensary
5 Lyubimova St., Ivanovo 153040
Russian FederationV. I. Vladimirov
Pyatigorsk Regional Oncology Dispensary
31 Prospekt Kalinina, Pyatigorsk 357502
Russian FederationA. Yu. Vorontsov
Nizhny Novgorod Regional Clinical Oncology Dispensary
11 / 1 Delovaya St., Nizhny Novgorod 603093
Russian FederationE. A. Gaysina
Multidisciplinary Clinical Medical Center «Medical City»
32 Barnaulskaya St., Tyumen 625041
Russian FederationA. A. Gofman
Altai Regional Oncology Dispensary
110k Zmeinogorskiy Trakt, Barnaul 656045
Russian FederationV. N. Dmitriev
Belgorod Regional Oncology Dispensary
ORCID iD: 0000-0002-5523-5718
1 Kuybysheva St., Belgorod 308010
Russian FederationE. N. Imyanitov
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
ORCID iD: 0000-0003-4529-7891
68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758
Russian FederationV. V. Klimenko
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
ORCID iD: 0000-0003-1079-4492
68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758
Russian FederationA. V. Komyakhov
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
ORCID iD: 0000-0002-6598-1669
68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758
Russian FederationM. M. Konstantinova
Public organization «Russian Society of Oncomammologists»
56 Prospekt Veteranov, Saint Petersburg 198255
Russian FederationM. V. Kopp
Private Medical University «Reaviz»
ORCID iD: 0000-0002-2783-9493
227 Chapaevskaya St., Samara 443001
Russian FederationA. G. Kudaybergenova
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
ORCID iD: 0000-0001-7797-088X
68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758
Russian FederationI. A. Lalak
Stavropol Regional Clinical Oncology Dispensary
182а Oktyabrskaya St., Stavropol 355047
Russian FederationD. L. Matevosyan
Pyatigorsk Regional Oncology Dispensary
31 Prospekt Kalinina, Pyatigorsk 357502
Russian FederationN. M. Mudzhiri
Research Center of Neurology
ORCID iD: 0000-0002-3835-6622
80 Volokolamskoe Shosse, Moscow 125367
Russian FederationO. V. Poltareva
Ivanovo Regional Oncology Dispensary
5 Lyubimova St., Ivanovo 153040
Russian FederationO. I. Sevryukova
Stavropol Regional Clinical Oncology Dispensary
182а Oktyabrskaya St., Stavropol 355047
Russian FederationV. F. Semiglazov
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
ORCID iD: 0000-0003-0077-9619
68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758
Russian FederationT. Yu. Semiglazova
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
ORCID iD: 0000-0002-4305-6691
68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758
Russian FederationM. M. Urezkova
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
ORCID iD: 0000-0002-4242-2629
68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758
Russian FederationA. S. Chichkanova
Nizhny Novgorod Regional Clinical Oncology Dispensary
11 / 1 Delovaya St., Nizhny Novgorod 603093
Russian FederationL. A. Churilova
Altai Regional Oncology Dispensary
110k Zmeinogorskiy Trakt, Barnaul 656045
Russian FederationM. V. Shomova
Regional Clinical Oncology Dispensary
ORCID iD: 0000-0002-6235-0925
11 Sportivnaya St., Ryazan 390011
Russian FederationReferences
- Bertucci F., Finetti P., Cervera N. Gene expression profiling and clinical outcome in breast cancer. J Int Biology 2006;4(10):429–43. doi: 10.1089/omi.2006.10.429
- Cowin P.A., Anglesio M., Etemadmoghadam D. Profiling the cancer genome. Ann Rev Gen Hum Genet 2010;11:133–59. doi: 10.1146/annurev-genom-082509-141536
- Van de Vijver M.J. Molecular tests as prognostic factors in breast cancer. Virchows Arch 2014;464(3):283–91. doi: 10.1007/s00428-014-1539-0
- Hurvitz S.A., Gonçalves A., Rugo H.S. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist 2020;25(3):439–50. doi: 10.1634/theoncologist.2019-0493
- Paltuev R.M., Aleksakhina S.N., Artemyeva A.S. et al. Predictive multigenic scale. Analysis of own results in metastatic breast cancer. Opukholi zhenskoy reproduktivnoy systemy = Tumors of female reproductive system 2023;19(1):69–81. (In Russ.). doi: 10.17650/1994-4098-2023-19-1-69-81
- Modi Sh., Jacot W., Yamashita T. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387(1):9–20. doi: 10.1056/NEJMoa2203690
- Schettini F., Chic N., Brasó-Maristany F. et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. Breast Cancer 2021;7(1):1. doi: 10.1038/s41523-020-00208-2
- Rakha E.A., Tan P.H., Quinn C. et al. UK recommendations for HER2 assessment in breast cancer: an update. J Clin Pathol 2023;76(4):217–27. doi: 10.1136/jcp-2022-20863
- Martinez-Sáez O., Chic N., Pascual T. et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res 2020;22(1):45. doi: 10.1186/s13058-020-01284-9
- Perez-Fidalgo J.A., Criscitiello C., Carrasco E. et al. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer. Future Oncol 2022;18(19):2339–49. doi: 10.2217/fon-2022-0045
Supplementary files
